Stage III Lung Cancer
12
3
4
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
16.7%
2 terminated out of 12 trials
60.0%
-26.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (12)
A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC
Assessing and Addressing Follow-up Care Needs That Will Facilitate Care Transitions for Cancer Survivors
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Ask Questions (ASQ):Implementation of a Communication Intervention
Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
External ValidatIon Trial of ASTER Trial
Lung Cancer Informational Study (LCIS)